Evidence map›Paper›PMID 39729102›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2025

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.

B T Baune, S E Fromme, M Aberg, M Adli, A Afantitis, I Akkouh, O A Andreassen, C Angulo, S Barlati, C Brasso and 65 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Precision medicine in mental health: applications, challenges, and recommendations.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

75 authors.

B T BauneDepartment of Psychiatry, University of Muenster, Muenster, Germany. Bernhard.Baune@uni-muenster.de.ORCID http://orcid.org/0000-0001-6548-426X
S E FrommeDepartment of Psychiatry, University of Muenster, Muenster, Germany.
M AbergDepartment of Medical Science, Clinical Chemistry and SciLifeLab Affinity Proteomics, Uppsala University, Uppsala, Sweden.
M AdliDepartment of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany.
A AfantitisDepartment of Chemoinformatics, NovaMechanics MIKE, Piraeus, Greece.
I AkkouhDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
O A AndreassenCentre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo, and Oslo University Hospital Oslo, Oslo, Norway.
C AnguloGlobal Alliance of Mental Illness Advocacy Networks Europe, Brussels, Belgium.
S BarlatiDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
C BrassoDepartment of Neuroscience, University of Turin, Turin, Italy.
P BucciDepartment of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
M BuddeInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital Munich, Munich, Germany.
P BuspavanichDepartment of Psychiatry, Psychosomatic and Psychotherapy, Brandenburg Medical School, Neuruppin, Germany.
V CavoneDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
K DemyttenaereKU Leuven and University Psychiatric Center KU Leuven, Leuven, Belgium.
C M Diaz-CanejaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
M DierssenUniversitat Pompeu Fabra, Barcelona, Spain.
S DjurovicDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
M DriessenDepartment of Psychiatry and Psychotherapy, Ev. Hospital Bethel, Bielefeld University, Bielefeld, Germany.
U W Ebner-PriemerMental mHealth Lab, Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.
J EngelmannDepartment of Psychiatry and Psychotherapy, University Medical Center, University of Mainz, Mainz, Germany.
S EnglischDepartment of Psychiatry and Psychotherapy, University Medical Center, University of Mainz, Mainz, Germany.
C FabbriDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
P FossatiDepartment of Psychiatry, Paris Brain Institute - Institut du Cerveau (ICM), UMR 7225/UMRS 1127, Sorbonne University/CNRS/INSERM, DMU Neurosciences, Pitié-Salpétrièren, APHP, Paris, France.
H FröhlichDepartment of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Sankt Augustin, Germany.
S GasserDepartment of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Innsbruck, Austria.
N GottliebDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
E HeirmanKU Leuven and University Psychiatric Center KU Leuven, Leuven, Belgium.
A HoferDepartment of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Innsbruck, Austria.
O HowesDepartment of Psychosis Studies, King's College London, London, UK.
L IlzarbeBipolar and Depressive Disorders Unit, Institute of Neurosciences, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
H Jeung-MaarseDepartment of Psychiatry and Psychotherapy, Ev. Hospital Bethel, Bielefeld University, Bielefeld, Germany.
L V KessingPsychiatric Center Copenhagen, Copenhagen, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
T D KocklerMental mHealth Lab, Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.
M LandénInstitute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
L LeviDrora and Pinchas Zachai Division of Psychiatry, Sheba Medical Center, Ramat-Gan, Israel.
K LiebDepartment of Psychiatry and Psychotherapy, University Medical Center, University of Mainz, Mainz, Germany.
N LorenzonCentre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
J LuykxDepartment of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands.
M ManchiaUnit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
M Martinez de LagranCentre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
A MinelliDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
C MorenoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
A MucciDepartment of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
B Müller-MyhsokStatistical Genetics, Max Planck Institute of Psychiatry, Munich, Germany.
P NilssonDivision of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.
C Okhuijsen-PfeiferDepartment of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
K D PapavasileiouDepartment of Chemoinformatics, NovaMechanics MIKE, Piraeus, Greece.
S PapiolInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital Munich, Munich, Germany.
A F PardinasCentre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
P ParibelloUnit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
C PisanuDepartment of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.
M-C PotierInstitut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de La Pitié Salpêtrière, Sorbonne Université, Paris, France.
A ReifDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany.
R RickenDepartment of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany.
S RipkeDepartment of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany.
P RoccaDepartment of Neuroscience, University of Turin, Turin, Italy.
D ScherrerUniversity Clinic of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
C SchiweckDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany.
K O SchubertDiscipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.
T G SchulzeInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital Munich, Munich, Germany.
A SerrettiDepartment of Medicine and Surgery, Kore University of Enna, Enna, Italy.
A SquassinaDepartment of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.
C StephanKairos GmbH, Bochum, Germany.
A TsoumanisDepartment of Chemoinformatics, NovaMechanics MIKE, Piraeus, Greece.
E Van der EyckenGlobal Alliance of Mental Illness Advocacy Networks Europe, Brussels, Belgium.
E VietaDepartment of Psychiatry and Psychology, Institute of Neuroscience (UBNeuro), Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
A VitaDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
J T R WaltersCentre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
D WeichertDepartment of Psychiatry and Psychotherapy, University Medical Center, University of Mainz, Mainz, Germany.
M WeiserDrora and Pinchas Zachai Division of Psychiatry, Sheba Medical Center, Ramat-Gan, Israel.
I R WillcocksCentre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
I Winter-van RossumDepartment of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
A H YoungDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
M J ZillerDepartment of Psychiatry, University of Muenster, Muenster, Germany.

Funding

Agence Nationale de la Recherche ANR-10-AIHU-06Departament de Salut, Generalitat de Catalunya SLD044/20/000001Fundació la Marató de TV3 202212-30HORIZON EUROPE Framework Programme 101057454
6 · The paper itself

Abstract

Schizophrenia (SCZ), bipolar (BD) and major depression disorder (MDD) are severe psychiatric disorders that are challenging to treat, often leading to treatment resistance (TR). It is crucial to develop effective methods to identify and treat patients at risk of TR at an early stage in a personalized manner, considering their biological basis, their clinical and psychosocial characteristics. Effective translation of theoretical knowledge into clinical practice is essential for achieving this goal. The Psych-STRATA consortium addresses this research gap through a seven-step approach. First, transdiagnostic biosignatures of SCZ, BD and MDD are identified by GWAS and multi-modal omics signatures associated with treatment outcome and TR (steps 1 and 2). In a next step (step 3), a randomized controlled intervention study is conducted to test the efficacy and safety of an early intensified pharmacological treatment. Following this RCT, a combined clinical and omics-based algorithm will be developed to estimate the risk for TR. This algorithm-based tool will be designed for early detection and management of TR (step 4). This algorithm will then be implemented into a framework of shared treatment decision-making with a novel mental health board (step 5). The final focus of the project is based on patient empowerment, dissemination and education (step 6) as well as the development of a software for fast, effective and individualized treatment decisions (step 7). The project has the potential to change the current trial and error treatment approach towards an evidence-based individualized treatment setting that takes TR risk into account at an early stage.

Indexed as

AlgorithmsBipolar DisorderMajor Depressive DisorderPharmacogeneticsPrecision MedicineSchizophreniaEuropeHumansDepression schizophreniaEarly detectionEarly treatmentPrecision psychiatryTreatment resistance

Identifiers

PMID39729102
PMCPMC12271288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.